Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects , anticipates , believes , intends , estimates , plans , will be and similar expressions. Although Sanofi s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict a
Novartis International AG: Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Novartis secures development and commercialization rights in North America, Europe, and Japan
Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
Tislelizumab already approved for patients with classical Hodgkin s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors
Basel, January 11, 2021 - Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. In pre-clinical studies, binding to Fc?R on macro
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth
Novartis secures development and commercialization rights in North America, Europe, and Japan
Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors
Basel, January 11, 2021 Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti
Caesars Wins US Antitrust Approval for William Hill Takeover, Eyes March Completion
By Todd Shriber - casino.org
Caesars Entertainment (NASDAQ:CZR) said Monday it cleared the antitrust waiting period for its proposed $3.69 billion acquisition of William Hill (OTC:WIMHY), putting it one step closer to creating a US sports betting behemoth.
Caesars Entertainment (NASDAQ:CZR) said Monday it cleared the antitrust waiting period for its proposed $3.69 billion acquisition of William Hill (OTC:WIMHY), putting it one step closer to creating a US sports betting behemoth.
Under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act), there are stretches of time when mergers and acquisitions are examined for potential anti-competitive conflicts. But Caesars cleared that regulatory hurdle sooner than expected.
Share this article
Share this article
RENO, Nev. and LAS VEGAS, Dec. 28, 2020 /PRNewswire/ Caesars Entertainment, Inc., (NASDAQ: CZR) ( Caesars, CZR, CEI or the Company ) announces the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ( HSR Act ) relating to the proposed combination with William Hill PLC, effective December 28, 2020.
The proposed combination also received approvals from the Mississippi Gaming Commission on November 19, 2020 and the West Virginia Lottery on December 16, 2020. The transaction remains subject to the satisfaction of the remaining conditions, including approval by the Indiana Gaming Commission, Nevada Gaming Control Board, Nevada Gaming Commission, New Jersey Division of Gaming Enforcement and Casino Control Commission, and the Pennsylvania Gaming Control Board. Additionally, the combination requires the English High Court s final approval and administrative and post-closing approvals from